Literature DB >> 17260229

Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer.

Hyun Hoon Chung1, Jae Weon Kim, Noh-Hyun Park, Yong-Sang Song, Soon-Beom Kang, Hyo-Pyo Lee.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the predictive value of preoperative serum CA-125 levels in the assessment of disease extent and clinical outcome of endometrial cancer.
METHOD: This retrospective study evaluated 92 women with pathologically proven endometrial carcinoma scheduled for treatment that had preoperative serum CA-125 levels between January 1999 and February 2006. The association of preoperative serum CA-125 with a variety of histopathologic factors was evaluated. Statistical analysis was performed using chi2/Fisher's exact test and a logistic regression. Survival was studied with the Kaplan-Meier method and Cox regression models.
RESULTS: Elevated serum CA-125 levels were significantly correlated with advanced-stage disease (p<0.001), lymph node metastases (p<0.001), increased depth of myometrial invasion (p=0.001), and positive peritoneal cytology (p=0.026). Multivariate analyses using logistic regression showed that lymph node metastases had the most significant effect on the elevation of preoperative serum CA-125 levels (p=0.004). Patients with a serum CA-125 < or =28.5 U/ml had a significantly better five-year disease-free survival than those with an elevated level in this study: 85.6% versus 60.0% (p=0.004).
CONCLUSIONS: The preoperative serum CA-125 level appears to be a significant independent predictor of lymph node metastasis and prognosis after surgical intervention. Therefore, preoperative serum CA-125 may be a useful tool, in the clinical setting, for optimal individualized patient management.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17260229     DOI: 10.1080/00016340601022777

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  28 in total

1.  Current status in the management of uterine corpus cancer in Korea.

Authors:  Nan-Hee Jeong; Jong-Min Lee; Seon-Kyung Lee
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Authors:  Sarah J Nyante; Amanda Black; Aimée R Kreimer; Máire A Duggan; J Daniel Carreon; Bruce Kessel; Saundra S Buys; Lawrence R Ragard; Karen A Johnson; Barbara K Dunn; Lois Lamerato; John M Commins; Christine D Berg; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2010-12-07       Impact factor: 5.482

3.  Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation.

Authors:  Emsal Pınar Topdağı Yılmaz; Yakup Kumtepe
Journal:  Eurasian J Med       Date:  2016-10

4.  Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Casper Reijnen; Joanna IntHout; Leon F A G Massuger; Fleur Strobbe; Heidi V N Küsters-Vandevelde; Ingfrid S Haldorsen; Marc P L M Snijders; Johanna M A Pijnenborg
Journal:  Oncologist       Date:  2019-06-11

5.  Prediction of staging with preoperative parameters and frozen/section in patients with a preoperative diagnosis of grade 1 endometrioid tumor in endometrial cancer.

Authors:  Alper Karalok; Işın Ureyen; Yıldız Reis; Ozge Oktay; Taner Turan; Nurettin Boran; Dilek Bülbül; Gökhan Tulunay; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-01-30

6.  Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies.

Authors:  Daye Cheng; Ying Sun; Hu He
Journal:  Med Oncol       Date:  2014-11-21       Impact factor: 3.064

7.  Serum amyloid A: a novel biomarker for endometrial cancer.

Authors:  Emiliano Cocco; Stefania Bellone; Karim El-Sahwi; Marilisa Cargnelutti; Natalia Buza; Fattaneh A Tavassoli; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

8.  The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.

Authors:  Beyhan Omer; Sema Genc; Ozguc Takmaz; Ahmet Dirican; Zeynep Kusku-Kiraz; Sinan Berkman; Figen Gurdol
Journal:  Tumour Biol       Date:  2013-05-03

9.  Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer.

Authors:  Shu-Ming He; Fuqi Xing; Hong Sui; Youming Wu; Yongli Wang; Dong Wang; Guanghui Chen; Zijing Kong; Shu-Feng Zhou
Journal:  Med Sci Monit       Date:  2011-11

10.  Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas.

Authors:  E Bignotti; A Ravaggi; R A Tassi; S Calza; E Rossi; M Falchetti; C Romani; E Bandiera; F E Odicino; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.